Russian pharmaceutical company Pharmapark, a company owned by Pharmstandard, and Singapore-based group Prestige Biopharma, entered into a licensing agreement for the delivery of a bioanalogue of trastuzumab to Russia. It is used to treat HER2-positive breast cancer.
Under the terms of the agreement, Pharmapark will deal with regulatory issues, marketing and evaluate the prospects for localizing the drug’s production in Russia. Other terms of the transaction are not disclosed.
Last week, Prestige BioPharma announced that it has reached similar licensing agreement with Mundipharma for its trastuzumab biosimilar (HD201) under which Mundipharma will have exclusive rights to distribute and market the drug in selected European markets.
The agreement allows the Mundipharma network to distribute, market and sell Tuznue in selected European countries following marketing authorisation, including France, Spain, Norway, Sweden, Denmark, Finland, Portugal, Switzerland and Austria.
About Prestige BioPharma
Prestige BioPharma is a Singapore-based biopharmaceutical company focusing on the development of biosimilars and new antibody therapeutics. Its lead program, HD201 Trastuzumab biosimilar, is under Phase 3 clinical development and has been filed with EMA while USFDA filing is in progress. Prestige BioPharma´s next products in line include a Bevacizumab biosimilar (HD204) in Phase 3, an Adalimumab biosimilar (PBP1502) and an innovative anti-PAUF mAb (PBP1510) for the treatment of pancreatic cancer ready for clinical development. Manufacturing facilities for global commercial supply are located in Osong, South Korea.
Pharmapark LLC is a private Russian pharmaceutical company. The company was set up in 2001, and is engaged in development and manufacturing of recombinant biopharmaceutical substances and finished medicinal products using these substances as active ingredients. The company also provides services in biopharmaceutical drug development. Its products are either included in the national list of vital and essential medicines or are used for their manufacturing. Pharmapark holds a national GMP certificate (GMP-0010-000268/18).